The stock of Protagonist Therapeutics Inc. (NASDAQ:PTGX) increased by $0.11 on Friday to finish at $18.91, up 0.59 percent. The last five days have seen an average of 656,960 shares of common stock traded. 32 times new highs were reached in the current year, with a gain of $8.00. The average number of shares traded over the last 20 days was 699,585, while the average volume over the last 50 days totaled 1,170,300.
PTGX stock dropped -11.61% since last month. On 08/09/23, the company’s shares reached a one-month low of $17.82. The stock touched a high of $30.10 on 06/12/23, after rallying from a low of $7.24 in 52 weeks. The price of PTGX stock has risen by 73.33% or $8.00 this year, reaching a new high 32 times. Still, the stock price is down -37.18% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended June 29, Protagonist Therapeutics Inc.’s quick ratio was 12.00, while its current ratio was 12.00, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $157.95 million and revenue of $26.58 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. PTGX’s return on assets (ROA) during the last 12 months has been -50.50%. There was a -60.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -56.80%.
Earnings Surprise
According to Protagonist Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $78.02 million in cash and short-term investments. It was predicted that Protagonist Therapeutics Inc.’s quarterly earnings would be -$0.68, but it ended up being -$0.65, beating the consensus by -4.60%. EBITDA was -$42.49 million for the quarter. At the end of Protagonist Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 26.4 million, while its total debt was $2.45 million. Equity owned by shareholders amounts to $57.53 million.
Technical Picture
Here’s a quick look at Protagonist Therapeutics Inc.’s (PTGX) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 41.54%, suggesting the stock is Neutral, with a 36.15% historical volatility rate.
The stochastic %K and %D were 37.01% and 26.42% respectively, while the average true range (ATR) was 0.84. Based on the 14-day stochastic reading of 51.66%, the RSI (14) reading is 37.05%. On the 9-day MACD Oscillator, the stock is at -0.06, and the 14-day reading is at -0.22.
Analyst Ratings
Analysts have assigned Protagonist Therapeutics Inc. (PTGX) an Buy rating. PTGX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 6 others recommend it as a buy.
What is PTGX’s price target for the next 12 months?
The current consensus forecast for the stock is between $35.00 and $49.00, with a median target price of $37.00. In analyzing these forecasts, the average price target given by analysts for Protagonist Therapeutics Inc. (PTGX) is $39.00.
